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Metabolic Syndrome Associated With Lipid-Rich Plaques
Although the metabolic syndrome (MetS) is known to increase the risk offuture cardiovascular events, little is known about its effects on the
components of atherosclerotic plaques. Amano and colleagues performed
integrated backscatter intravascular ultrasound on non-hemodynamically sig-
nificant lesions in patients with and without criteria for MetS. Although the
percent diameter stenoses were similar, those with MetS had higher percent-
ages of lipid in the plaque and reduced areas of fibrosis. These lipid-rich
plaques are thought to be more prone to rupture and may explain some of the
increased risk seen with MetS. See page 1149.
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Hypertension
Efficacy of Aliskiren for Blood Pressure Control
Aliskiren is an orally bioavailable renin inhibitor that is being investigatedfor the treatment of hypertension. This 8-week trial investigated the safety
and efficacy of aliskiren in patients with hypertension. The 300-mg dose
provided a significant reduction of 14.7 mmHg for systolic blood pressure and
11.1 mm Hg for diastolic blood pressure, with sustained 24-h efficacy. The
adverse event rate was similar to placebo. Aliskiren provides significant blood
pressure-lowering effects and appears to be well tolerated; its long serum
half-life and sustained blood pressure lowering show great promise for the
treatment of hypertension. See page 1157. See figure.
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Heart Failure
ACE Inhibitors May Help to Wean From LVAD Support
Although left ventricular assist devices (LVADs) can serve as a bridge totransplant, only a small minority of patients are able to be successfully
weaned. Klotz and colleagues hypothesized that there may be further deterio-
ration in the properties of the extracellular matrix (ECM) during LVAD use
and that angiotensin-converting enzyme (ACE) inhibitors might reverse this
deterioration. Pre- and post-LVAD cardiac biopsy specimens were compared
as were the passive pressure volume loops of explanted hearts. Hearts treated
with ACE inhibitors had reduced levels of angiotensin II and cross-linked
collagen. Left ventricular mass and myocardial stiffness were also improved by
ACE inhibitor usage. Angiotensin-converting enzyme inhibitors may be useful
in restoring properties of the ECM such that LVADs may be used as a bridge
to recovery, rather than a bridge to transplant. See page 1166. See figure.
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Utility of Various BNP Sampling Protocols
Two articles in this issue assess the prognostic utility of novel B-type natriureticpeptide (BNP) testing protocols. Kwan and colleagues examined the utility of
short-term changes in BNP levels to aid in the risk-stratification of patients presenting
with chest pain. Whereas elevated BNP levels strongly predicted subsequent adverse
events, therewas nobenefit to serialmeasurements in the first 24h. Lamand colleagues
noted that both circulating BNP and N-terminal-pro-B-type natriuretic peptide may
be cleaved by aminodipeptidases, removing the first 2 amino acids. They developed
assays to measure these products and compared the diagnostic utility of these proteins
versus standard BNP assays. The cleaved forms of BNP were found in a minority of
both control subjects and those with heart failure, however, neither was superior to
commercially available assays for the detection of heart failure. Although both of these
studies add to our understanding of the release and processing of BNP, neithermethod
improves on the diagnostic utility of currently available methods. See pages 1186
and 1193.
